SCHEMBL3085669

SCHEMBL3085669

Fc1ccc(-c2csc3nccn23)cc1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 3/20 0.71
FLT3 P36888 4/20 0.41
PRKD3 O94806 1/20 0.40
MAP4K4 O95819 1/20 0.40
FGFR1 P11362 1/20 0.40
FRK P42685 1/20 0.40
MAPK8 P45983 1/20 0.40
MAPK9 P45984 1/20 0.40
CSNK1A1 P48729 1/20 0.40
CSNK1D P48730 1/20 0.40
GSK3B P49841 1/20 0.40
CSNK1G2 P78368 1/20 0.40
PRKCD Q05655 1/20 0.40
ERBB4 Q15303 1/20 0.40
MINK1 Q8N4C8 1/20 0.40
PRKD2 Q9BZL6 1/20 0.40
CSNK1G1 Q9HCP0 1/20 0.40
MAP3K20 Q9NYL2 1/20 0.40
CSNK1G3 Q9Y6M4 1/20 0.40
CA12 O43570 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL567443 0.83 IDO1 (0.71) IDO1MAP4K4GSK3BCA12CA1
SCHEMBL9292362 0.71 KDM4E (0.50) PRKD3MAP4K4FGFR1FRKMAPK8
SCHEMBL6668609 0.70 IDO1 (0.54) IDO1ALDH1A1POLBHPGDMAPT
SCHEMBL3079689 0.67 FLT3 (0.44) FLT3ALDH1A1POLBHPGDCSNK1E
SCHEMBL5313030 0.65
SCHEMBL12670528 0.65
SCHEMBL5404541 0.65 TTK (0.56) FLT3ALDH1A1CSNK1ECCNT1CCNA2
SCHEMBL3085667 0.64 FLT3 (0.38) FLT3ALDH1A1HPGDKDM4ENPC1
SCHEMBL18083273 0.63 KDM4E (0.51) CA12CA1CA2CA9ALDH1A1
SCHEMBL5412317 0.62 FLT3 (0.46) FLT3ALDH1A1HPGDCSNK1ECCNT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023093700-A1 IMIDAZOTHIAZOLE DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF 中国海洋大学 2023-06-01 WO disclosed
US-7790741-B2 Imidazothiazoles and imidazoxazoles ABBOTT LABORATORIES (US) 2010-09-07 US disclosed
US-20080161341-A1 Novel imidazothiazoles and imidazoxazoles ABBVIE INC. 2008-07-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080161341-A1 Novel imidazothiazoles and imidazoxazoles MAP3K1, MAP3K19, MAP3K5 IDO1 1304/4885FLT3 273/4885PRKD3 376/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.